Your browser doesn't support javascript.
loading
Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review.
Shitara, Kohei; Falcone, Alfred; Fakih, Marwan G; George, Ben; Sundar, Raghav; Ranjan, Sandip; Van Cutsem, Eric.
Afiliação
  • Shitara K; National Cancer Center Hospital East, Chiba, Japan.
  • Falcone A; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Fakih MG; University of Pisa, Pisa, Italy.
  • George B; City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Sundar R; Medical College of Wisconsin, Milwaukee, WI, USA.
  • Ranjan S; Department of Haematology-Oncology, National University Cancer Institute, Singapore, National University Hospital, Singapore.
  • Van Cutsem E; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore.
Oncologist ; 29(5): e601-e615, 2024 May 03.
Article em En | MEDLINE | ID: mdl-38366864
ABSTRACT
We performed a systematic literature review to identify and summarize data from studies reporting clinical efficacy and safety outcomes for trifluridine/tipiracil (FTD/TPI) combined with other antineoplastic agents in advanced cancers, including metastatic colorectal cancer (mCRC). We conducted a systematic search on May 29, 2021, for studies reporting one or more efficacy or safety outcome with FTD/TPI-containing combinations. Our search yielded 1378 publications, with 38 records meeting selection criteria 35 studies of FTD/TPI-containing combinations in mCRC (31 studies second line or later) and 3 studies in other tumor types. FTD/TPI plus bevacizumab was extensively studied, including 19 studies in chemorefractory mCRC. Median overall survival ranged 8.6-14.4 months and median progression-free survival 3.7-6.8 months with FTD/TPI plus bevacizumab in refractory mCRC. Based on one randomized and several retrospective studies, FTD/TPI plus bevacizumab was associated with improved outcomes compared with FTD/TPI monotherapy. FTD/TPI combinations with chemotherapy or other targeted agents were reported in small early-phase studies; preliminary data indicated higher antitumor activity for certain combinations. Overall, no safety concerns existed with FTD/TPI combinations; most common grade ≥ 3 adverse event was neutropenia, ranging 5%-100% across all studies. In studies comparing FTD/TPI combinations with monotherapy, grade ≥ 3 neutropenia appeared more frequently with combinations (29%-67%) vs. monotherapy (5%-41%). Discontinuation rates due to adverse events ranged 0%-11% for FTD/TPI plus bevacizumab and 0%-17% with other combinations. This systematic review supports feasibility and safety of FTD/TPI plus bevacizumab in refractory mCRC. Data on non-bevacizumab FTD/TPI combinations remain preliminary and need further validation.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirrolidinas / Timina / Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Trifluridina / Combinação de Medicamentos Limite: Humans Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirrolidinas / Timina / Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Trifluridina / Combinação de Medicamentos Limite: Humans Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão